Pneumonia, thrombosis and vascular disease

An enhanced risk of cardiovascular mortality has been observed after pneumonia. Epidemiological studies have shown that respiratory tract infections are associated with an increased risk of thrombotic‐related vascular disease such as myocardial infarction, ischemic stroke and venous thrombosis. Myocardial infarction and stroke have been detected essentially in the early phase of the disease (i.e. within 48 h from hospital admission), with an incidence ranging from as low as 1% to as high as 11%. Age, previous cardiovascular events and high pneumonia severity index were independent predictors of myocardial infarction; clinical predictors of stroke were not identified. Deep venous thrombosis and pulmonary embolism may also occur after pneumonia but incidence and clinical predictors must be defined. The biological plausibility of such an association may be deduced by experimental and clinical studies, showing that lung infection is complicated by platelet aggregation and clotting system activation, as documented by up‐regulation of tissue factor and down‐regulation of activated protein C. The effect of antithrombotic drugs has been examined in experimental and clinical studies but results are still inconclusive.

[1]  P. Palange,et al.  Is NOX2 upregulation implicated in myocardial injury in patients with pneumonia? , 2014, Antioxidants & redox signaling.

[2]  T. van der Poll,et al.  The endothelial protein C receptor impairs the antibacterial response in murine pneumococcal pneumonia and sepsis , 2014, Thrombosis and Haemostasis.

[3]  M. Fine,et al.  The Association of Cardioprotective Medications with Pneumonia-Related Outcomes , 2014, PloS one.

[4]  G. Viegi,et al.  Risk factors for community-acquired pneumonia in adults in Europe: a literature review , 2013, Thorax.

[5]  D. Musher,et al.  Acute pneumonia and the cardiovascular system , 2013, The Lancet.

[6]  C. Esmon,et al.  Endogenous protein C has a protective role during Gram‐negative pneumosepsis (melioidosis) , 2013, Journal of thrombosis and haemostasis : JTH.

[7]  R. Charnigo,et al.  Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness , 2013, Journal of Thrombosis and Thrombolysis.

[8]  F. Violi,et al.  Statins as Antithrombotic Drugs , 2013, Circulation.

[9]  P. Erwin,et al.  The Role of Statins in Prevention and Treatment of Community Acquired Pneumonia: A Systematic Review and Meta-Analysis , 2013, PloS one.

[10]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[11]  P. Chou,et al.  Pneumococcal Pneumonia and the Risk of Stroke: A Population-Based Follow-Up Study , 2012, PloS one.

[12]  B. Pozzetto,et al.  Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion. , 2012, Clinical immunology.

[13]  A. Kalil,et al.  Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. , 2012, The Lancet. Infectious diseases.

[14]  R. Rumbaut,et al.  Platelet-Derived Toll-Like Receptor 4 (Tlr-4) Is Sufficient to Promote Microvascular Thrombosis in Endotoxemia , 2012, PloS one.

[15]  S. Basili,et al.  Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2 , 2012, Circulation.

[16]  F. Rosendaal,et al.  Pneumonia and risk of venous thrombosis: results from the MEGA study , 2012, Journal of thrombosis and haemostasis : JTH.

[17]  M. Fine,et al.  Cardiac Complications in Patients With Community-Acquired Pneumonia: Incidence, Timing, Risk Factors, and Association With Short-Term Mortality , 2012, Circulation.

[18]  Mark D. Williams,et al.  Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis. , 2011, Journal of critical care.

[19]  M. Rasmussen,et al.  Platelet and Neutrophil Responses to Gram Positive Pathogens in Patients with Bacteremic Infection , 2011, PloS one.

[20]  Tzeng-Ji Chen,et al.  Association Between Mycoplasma Pneumonia and Increased Risk of Ischemic Stroke: A Nationwide Study , 2011, Stroke.

[21]  T. van der Poll,et al.  Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia , 2011, Thrombosis and Haemostasis.

[22]  D. Angus,et al.  Elevated Hemostasis Markers after Pneumonia Increases One-Year Risk of All-Cause and Cardiovascular Deaths , 2011, PloS one.

[23]  S. Opal,et al.  Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. , 2011, American journal of respiratory and critical care medicine.

[24]  A. Akram,et al.  Vascular complications are associated with poor outcome in community-acquired pneumonia. , 2011, QJM : monthly journal of the Association of Physicians.

[25]  J. Oosterheert,et al.  Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[26]  A. Anzueto,et al.  Incidence of cardiovascular events after hospital admission for pneumonia. , 2011, The American journal of medicine.

[27]  T. Meade,et al.  Recent respiratory infection and risk of venous thromboembolism: case–control study through a general practice database , 2011, International journal of epidemiology.

[28]  Wendy Lim,et al.  The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. , 2011, Chest.

[29]  F. Castellino,et al.  The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. , 2010, Blood.

[30]  J. Ramirez,et al.  Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. , 2010, Chest.

[31]  J. Bastarache,et al.  Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[32]  R. Paterson.  Prior Statin Use is Associated with Improved Outcomes in Community-Acquired Pneumonia , 2009 .

[33]  G. Vail,et al.  Biomarkers of Thrombosis, Fibrinolysis, and Inflammation in Patients with Severe Sepsis due to Community-Acquired Pneumonia with and without Streptococcus pneumoniae , 2009, Infection.

[34]  M. Bauer,et al.  Anti-platelet drugs and outcome in severe infection: Clinical impact and underlying mechanisms , 2009, Platelets.

[35]  D. Musher,et al.  Acute Bacterial Pneumonia is Associated With the Occurrence of Acute Coronary Syndromes , 2008, Medicine.

[36]  P. Shashkin,et al.  Lipopolysaccharide Is a Direct Agonist for Platelet RNA Splicing1 , 2008, The Journal of Immunology.

[37]  J. Ramirez,et al.  Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  T. van der Poll,et al.  Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans. , 2008, American journal of respiratory and critical care medicine.

[39]  D. Angus,et al.  Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. , 2008, American journal of respiratory and critical care medicine.

[40]  T. Meade,et al.  Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. , 2007, European heart journal.

[41]  H. Gerstein,et al.  Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. , 2007, Diabetes research and clinical practice.

[42]  D. Musher,et al.  The association between pneumococcal pneumonia and acute cardiac events. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  T. Geiser,et al.  The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor , 2007, Thorax.

[44]  T. Mooe,et al.  Platelet aggregation and aspirin non‐responsiveness increase when an acute coronary syndrome is complicated by an infection , 2007, Journal of thrombosis and haemostasis : JTH.

[45]  F. Castellino,et al.  Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. , 2007, Blood.

[46]  W. Henderson,et al.  Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. , 2007, Journal of vascular surgery.

[47]  Timothy J. Foster,et al.  The interaction of bacterial pathogens with platelets , 2006, Nature Reviews Microbiology.

[48]  T. van der Poll,et al.  Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia* , 2006, Critical care medicine.

[49]  R. Hubbard,et al.  Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting , 2006, The Lancet.

[50]  C. Esmon,et al.  Inflammation and the activated protein C anticoagulant pathway. , 2006, Seminars in thrombosis and hemostasis.

[51]  G. Bernard,et al.  Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment* , 2005, Critical care medicine.

[52]  P. Kubes,et al.  Platelets express functional Toll-like receptor-4. , 2005, Blood.

[53]  P. Gurbel,et al.  Viral respiratory tract infections increase platelet reactivity and activation: an explanation for the higher rates of myocardial infarction and stroke during viral illness , 2005, Journal of thrombosis and haemostasis : JTH.

[54]  T. van der Poll,et al.  Activation of coagulation and inhibition of fibrinolysis in the lung after inhalation of lipopolysaccharide by healthy volunteers , 2005, Thrombosis and Haemostasis.

[55]  R. Wunderink,et al.  Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study* , 2005, Critical care medicine.

[56]  R. Hubbard,et al.  Risk of myocardial infarction and stroke after acute infection or vaccination. , 2004, The New England journal of medicine.

[57]  M. Loeb,et al.  Patients with severe sepsis vary markedly in their ability to generate activated protein C. , 2004, Blood.

[58]  B. Østerud,et al.  Tissue factor: (patho)physiology and cellular biology , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[59]  G. Escolar,et al.  Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. , 2004, Blood.

[60]  T. van der Poll,et al.  Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia , 2004, Thorax.

[61]  P. Carmeliet,et al.  Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. , 2003, Blood.

[62]  John Mullooly,et al.  Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. , 2003, The New England journal of medicine.

[63]  M. Byrne,et al.  A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation. , 2002, Blood.

[64]  M. Carraway,et al.  Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. , 2002, American journal of respiratory cell and molecular biology.

[65]  M. Fine,et al.  Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. , 2002, Archives of internal medicine.

[66]  D. Fitzgerald,et al.  Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine–aspartate repeat protein SdrE and protein A , 2002, Molecular microbiology.

[67]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[68]  H. Jick,et al.  Acute respiratory-tract infections and risk of first-time acute myocardial infarction , 1998, The Lancet.

[69]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[70]  C. Chopin,et al.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. , 1992, Chest.

[71]  Ignacio Chávez,et al.  International Society on Thrombosis and Haemostasis , 1974 .

[72]  J. Dorca,et al.  Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. , 2013, The Journal of infection.